B
Bernard Guillot
Researcher at University of Montpellier
Publications - 476
Citations - 9498
Bernard Guillot is an academic researcher from University of Montpellier. The author has contributed to research in topics: Melanoma & Allergic contact dermatitis. The author has an hindex of 43, co-authored 470 publications receiving 8351 citations. Previous affiliations of Bernard Guillot include French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases
Jean-Jacques Grob,Brigitte Dréno,Pauline de la Salmoniere,Michèle Delaunay,Didier Cupissol,Bernard Guillot,Pierre Souteyrand,Bruno Sassolas,Jean-Pierre Cesarini,Sylvie Lionnet,Catherine Lok,Claude Chastang,Jean Jacques Bonerandi +12 more
TL;DR: Adjuvant therapy of high-risk melanoma with low doses of interferon α-2a for 18 months is safe and is beneficial when started before clinically detectable node metastases develop.
Journal ArticleDOI
Dressings for acute and chronic wounds: a systematic review.
G. Chaby,Patricia Senet,Michel Vaneau,Philippe Martel,Jean-Claude Guillaume,Sylvie Meaume,Luc Téot,Clélia Debure,Anne Dompmartin,Hélène Bachelet,Hervé Carsin,Véronique Matz,Jean Louis Richard,Jean Michel Rochet,Nathalie Sales-Aussias,Anne Zagnoli,Catherine Denis,Bernard Guillot,Olivier Chosidow +18 more
TL;DR: The authors' systematic review provided only weak levels of evidence on the clinical efficacy of modern dressings compared with saline or paraffin gauze in terms of healing, with the exception of hydrocolloid dressings.
Journal ArticleDOI
Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.
Nicole Basset-Seguin,Axel Hauschild,Jean-Jacques Grob,Rainer Kunstfeld,Brigitte Dréno,Laurent Mortier,Paolo A. Ascierto,Lisa Licitra,Caroline Dutriaux,Luc Thomas,Thomas Jouary,Nicolas Meyer,Bernard Guillot,Reinhard Dummer,Kate Fife,D. Scott Ernst,Sarah Williams,Alberto Fittipaldo,Ioannis Xynos,Johan Hansson +19 more
TL;DR: Treatment with vismodegib adds a novel therapeutic modality from which patients with advanced basal cell carcinoma can benefit substantially and is designed to assess the safety of vismODEgib in a situation similar to routine practice, with a long follow-up.
Journal ArticleDOI
Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.
Nicole Basset-Seguin,Axel Hauschild,Rainer Kunstfeld,J.-J. Grob,B. Dréno,Laurent Mortier,P.A. Ascierto,Lisa Licitra,C. Dutriaux,Luc Thomas,Nicolas Meyer,Bernard Guillot,Reinhard Dummer,Petr Arenberger,Kate Fife,A. Raimundo,Emi Dika,N. Dimier,A. Fittipaldo,I. Xynos,Johan Hansson +20 more
TL;DR: The primary analysis of STEVIE demonstrates that vismodegib is tolerable in typical patients in clinical practice; safety profile is consistent with that in previous reports.
Journal ArticleDOI
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
Alexander M.M. Eggermont,Christian U. Blank,Mario Mandalà,Georgina V. Long,Victoria Atkinson,Stéphane Dalle,Andrew Haydon,Andrey Meshcheryakov,Adnan Khattak,Matteo S. Carlino,Shahneen Sandhu,James Larkin,Susana Puig,Paolo A. Ascierto,Piotr Rutkowski,Dirk Schadendorf,Rutger H. T. Koornstra,Leonel Hernandez-Aya,Anna Maria Di Giacomo,Alfonsus J M van den Eertwegh,Jean-Jacques Grob,Ralf Gutzmer,Rahima Jamal,Paul Lorigan,Alexander C.J. van Akkooi,Clemens Krepler,Nageatte Ibrahim,Sandrine Marreaud,Michal Kicinski,Stefan Suciu,Caroline Robert,Alex Menzies,Thierry Lesimple,Michele Maio,Gerald P. Linette,Michael C. Brown,Peter Hersey,Inge Marie Svane,Laurent Mortier,Jacob Schachter,Catherine Barrow,Ragini R. Kudchadkar,Xinni Song,Caroline Dutriaux,Pietro Quaglino,Friedegund Meier,Paola Queirolo,Daniil Stroyakovskiy,Lars Bastholt,Bernard Guillot,Claus Garbe,Pablo Luis Ortiz Romero,Florent Grange,Peter Mohr,Alain Algazi,Oliver Bechter,Micaela Hernberg,Jean-Philippe Arnault,Philippe Saiag,Carmen Loquai,Frank Meiss,Jan-Christoph Simon,Gil Bar-Sela,Vanna Chiarion Sileni,Bernard Fitzharris,Mike McCrystal,Phillip Parente,Jean-Francois Baurain,Patrick Combemale,Céleste Lebbé,Axel Hauschild,Naoya Yamazaki,Reinhard Dummer,Mohammed M. Milhem,Marcin Dzienis,John Walker,Lionel Geoffrois,Marie-Thérèse Leccia,Lutz Kretschmer,Daniel Hendler,Michal Lotem,Andrzej Mackiewicz,Lidija Sekulovic,Elaine Dunwoodie,Christoph Hoeller,Laurent Machet,Jessica C. Hassel,Geke A. P. Hospers,Maria-Jose Passos,Max Levin,Martin Fehr,Philippa Corrie,Ashita Waterston,Sigrun Hallmeyer,Henrik Schmidt,Vincent Descamps,Jean-Philippe Lacour,Carola Berking,Felix Kiecker,Pier Francesco Ferrucci,Kenji Yokota,Maureen J.B. Aarts,Michael B. Jameson,Anna Katharina Winge-Main,Paula Ferreira,Kevin B. Kim,Catriona M. McNeil,Reiner Hofmann-Wellenhof,Joseph Kerger,François Aubin,Jochen Utikal,Virginia Ferraresi,Takashi Inozume,Yoshio Kiyohara,Gerard Groenewegen,Helena Kapiteijn,Suzana Matkovic,Wolf-Henning Boehncke,Richard Casasola,Timothy Crook,Ernest Marshall,Tanja Skytta,Marie-Francoise Avril,Thomas Jouary,Rüdiger Hein,Patrick Terheyden,Jun Aoi,Tatsuya Takenouchi,Oddbjorn Straume,César Martins,Guzel Mukhametshina,Paul C. Nathan +131 more
TL;DR: In this paper, the authors compared pembrolizumab versus placebo in patients with resected high-risk stage III melanoma, and showed that penglizumaab adjuvant therapy provided a significant and clinically meaningful improvement in distant metastasis-free survival at a 3·5-year median followup.